Secretory full-length human prosaposin (PSAP) inhibits SARS-CoV-2 infection through facilitating the release of S1 subunit of spike protein
mBio · 13.05.2026 · 17 (5)
DOI: 10.1128/mbio.00129-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 13.05.2026. Verfasst von Chongyang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of System Biology of Pathogens and Christophe Merieux Laboratory, National Institute of Pathogen Biology, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Saposins, SARS-CoV-2, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Foundation for Innovative Research Groups of the National Natural Science Foundation of China, The CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted global public health and the economy. Systematic screening of host factors influencing viral infection is critical for understanding virus-host interactions and for developing host-targeted antiviral strategies. Here, we conducted a host cDNA overexpression screen to identify host factors involved in regulating SARS-CoV-2 replication. This approach identified prosaposin (PSAP), a precursor of lysosomal saposin activators (saposin A, B, C, and D), as an efficient host restriction factor that blocks SARS-CoV-2 entry. We demonstrate that PSAP binds with high affinity to the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein. Secreted PSAP efficiently inhibits infection by both SARS-CoV-2 pseudovirus and authentic virus. Mechanistically, PSAP binding facilitates the release of the S1 subunit from the S protein. Molecular docking analysis further revealed that PSAP interacts with the non-receptor-binding motif (non-RBM) region of the domain (RBD). These results suggest that PSAP inhibits SARS-CoV-2 entry through a mechanism analogous to that of neutralizing antibodies. Our findings highlight PSAP as a novel host restriction factor against SARS-CoV-2 infection, offering new insights into potential therapeutic strategies for combating SARS-CoV-2. IMPORTANCE The systematic identification of host factors that modulate SARS-CoV-2 infection is critical for elucidating the mechanisms of virus-host interaction and for advancing the development of novel host-directed therapeutic interventions. In this study, we identify the human protein prosaposin (PSAP) as a novel and potent innate restriction factor that effectively blocks SARS-CoV-2 infection. By binding with high affinity to the spike protein’s receptor-binding domain (RBD) at a unique site, PSAP neutralizes the virus, thereby preventing cellular entry. Consequently, this discovery establishes a foundation for a novel host-directed therapeutic strategy. The development of pharmacologic agents that recapitulate PSAP’s action could yield a new class of antivirals that neutralize SARS-CoV-2 by mechanistically disrupting spike protein integrity, offering a complementary approach to conventional antibody therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of System Biology of Pathogens and Christophe Merieux Laboratory, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic…
- State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Pathogen Infection Prevention and Control (Ministry of Education), National Institute of Pathogen Biology, Chinese Academy of Medical Scie…
- State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, People's Republic of China.
ORCID-Profile: Lili Ren, Xiaobo Lei, Jianwei Wang
Förderung
- the Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- The CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- Double Innovation Plan of Jiansu province
- Gusu Innovation and Entrepreneurship Leading Talents Program
Zitieren
APA
Zhang, C., Ding, P., Xiao, X., Wang, B., Huang, H., Zhang, Q., Ren, L., Xiang, Z., Zhou, Z., Lei, X., & Wang, J. (2026). Secretory full-length human prosaposin (PSAP) inhibits SARS-CoV-2 infection through facilitating the release of S1 subunit of spike protein. mBio, 17(5). https://doi.org/10.1128/mbio.00129-26
Vancouver
Zhang C, Ding P, Xiao X, Wang B, Huang H, Zhang Q, et al. Secretory full-length human prosaposin (PSAP) inhibits SARS-CoV-2 infection through facilitating the release of S1 subunit of spike protein. mBio. 2026;17(5). doi:10.1128/mbio.00129-26
BibTeX
@article{Zhang2026,
author = {Zhang, Chongyang and Ding, Peiwen and Xiao, Xia and Wang, Bei and Huang, He and Zhang, Qiao and Ren, Lili and Xiang, Zichun and Zhou, Zhuo and Lei, Xiaobo and Wang, Jianwei},
title = {Secretory full-length human prosaposin (PSAP) inhibits SARS-CoV-2 infection through facilitating the release of S1 subunit of spike protein},
journal = {mBio},
year = {2026},
volume = {17},
number = {5},
doi = {10.1128/mbio.00129-26}
}
EUVIMED